37 institutions hold shares in Zosano Pharma Corporation (ZSAN), with 745.09k shares held by insiders accounting for 0.70% while institutional investors hold 13.58% of the company’s shares. The shares outstanding are 102.32M, and float is at 101.70M with Short Float at 8.08%. Institutions hold 13.49% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 3.54 million shares valued at $1.87 million. The investor’s holdings represent 3.33% of the ZSAN Shares outstanding. As of Dec 30, 2020, the second largest holder is Aisling Capital Management LP with 2.72 million shares valued at $1.43 million to account for 2.56% of the shares outstanding. The other top investors are Blackrock Inc. which holds 1.11 million shares representing 1.04% and valued at over $0.58 million, while Adage Capital Partners GP L.L.C. holds 0.94% of the shares totaling 1.0 million with a market value of $0.53 million.
Zosano Pharma Corporation (NASDAQ: ZSAN) is 129.56% higher on its value in year-to-date trading and has touched a low of $0.33 and a high of $3.06 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ZSAN stock was last observed hovering at around $1.27 in the last trading session, with the day’s loss setting it -0.06% off its average median price target of $2.25 for the next 12 months. It is also 51.6% off the consensus price target high of $2.50 offered by 2 analysts, but current levels are 39.5% higher than the price target low of $2.00 for the same period.
Currently trading at $1.21, the stock is -4.61% and -5.89% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.14 million and changing -4.72% at the moment leaves the stock 18.41% off its SMA200. ZSAN registered 128.73% gain for a year compared to 6-month gain of 79.87%. The firm has a 50-day simple moving average (SMA 50) of $1.2994 and a 200-day simple moving average (SMA200) of $0.9266.
The stock witnessed a 1.68% loss in the last 1 month and extending the period to 3 months gives it a 50.29%, and is 0.83% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.36% over the week and 9.53% over the month.
Zosano Pharma Corporation (ZSAN) has around 45 employees, a market worth around $129.65M and $0.20M in sales. Distance from 52-week low is 269.47% and -60.46% from its 52-week high. The company has generated returns on investments over the last 12 months (-56.20%).
Zosano Pharma Corporation (ZSAN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Zosano Pharma Corporation (ZSAN) is a “Buy”. 2 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Zosano Pharma Corporation is expected to release its quarterly report on 08/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.07.The EPS is expected to grow by 78.60% this year, but quarterly earnings will post 1,739.30% year-over-year.
Zosano Pharma Corporation (ZSAN) Insider Activity
A total of 4 insider transactions have happened at Zosano Pharma Corporation (ZSAN) in the last six months, with sales accounting for 0 and purchases happening 4 times.